Skip to main content
Erschienen in: Clinical Journal of Gastroenterology 1/2021

28.10.2020 | Case Report

Ustekinumab is effective against small bowel lesions in Crohn’s disease: two case reports

verfasst von: Kentaro Murate, Masanao Nakamura, Takeshi Yamamura, Keiko Maeda, Tsunaki Sawada, Yasuyuki Mizutani, Eri Ishikawa, Naomi Kakushima, Kazuhiro Furukawa, Eizaburo Ohno, Takashi Honda, Hiroki Kawashima, Masatoshi Ishigami, Mitsuhiro Fujishiro

Erschienen in: Clinical Journal of Gastroenterology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

We encountered two patients with Crohn’s disease (CD) for whom induction of ustekinumab was effective for the management of small intestinal lesions with stenosis. The first symptomatic CD case was a 40-year-old female with longitudinal ulcers in the small bowel found at double-balloon endoscopy. She was in a biologic-naïve condition. Her symptoms improved immediately after ustekinumab induction. We confirmed the condition of intestinal mucosa by double-balloon endoscopy. Deep ulcers remained open at 24 weeks and were scarred at 72 weeks. The second case was a 50-year-old male who failed to respond to treatment with anti-TNFα agents. The lumen was narrow caused by circumferential ulcer, and an endoscope could not pass the site before induction. The circumferential ulcer had been healed by ustekinumab induction, and an endoscope passed through at 72 weeks. These two cases support the therapeutic efficacy of ustekinumab in alleviating small bowel lesions in CD patients.
Literatur
1.
Zurück zum Zitat Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(46–54):e42. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(46–54):e42.
2.
Zurück zum Zitat Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9.CrossRef Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9.CrossRef
3.
Zurück zum Zitat Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104:760–7.PubMed Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104:760–7.PubMed
4.
Zurück zum Zitat Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3:535–45.CrossRef Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3:535–45.CrossRef
5.
Zurück zum Zitat Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367:1519–28.CrossRef Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367:1519–28.CrossRef
6.
Zurück zum Zitat Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135:1130–41.CrossRef Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135:1130–41.CrossRef
7.
Zurück zum Zitat Ma C, Fedorak RN, Kaplan GG, et al. Long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe Crohn’s disease: real-world experience from a multicenter cohort study. Inflamm Bowel Dis. 2017;23:833–9.CrossRef Ma C, Fedorak RN, Kaplan GG, et al. Long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe Crohn’s disease: real-world experience from a multicenter cohort study. Inflamm Bowel Dis. 2017;23:833–9.CrossRef
8.
Zurück zum Zitat Lenti MV, Di Sabatino A. Intestinal fibrosis. Mol Aspects Med. 2019;65:100–9.CrossRef Lenti MV, Di Sabatino A. Intestinal fibrosis. Mol Aspects Med. 2019;65:100–9.CrossRef
9.
Zurück zum Zitat Sato Y, Matsui T, Yano Y, et al. Long-term course of Crohn’s disease in Japan: Incidence of complications, cumulative rate of initial surgery, and risk factors at diagnosis for initial surgery. J Gastroenterol Hepatol. 2015;30:1713–9.CrossRef Sato Y, Matsui T, Yano Y, et al. Long-term course of Crohn’s disease in Japan: Incidence of complications, cumulative rate of initial surgery, and risk factors at diagnosis for initial surgery. J Gastroenterol Hepatol. 2015;30:1713–9.CrossRef
10.
Zurück zum Zitat Takenaka K, Fujii T, Suzuki K, et al. Small bowel healing detected by endoscopy in patients with Crohn’s disease after treatment with antibodies against tumor necrosis factor. Clin Gastroenterol Hepatol. 2019;18:1545–52.CrossRef Takenaka K, Fujii T, Suzuki K, et al. Small bowel healing detected by endoscopy in patients with Crohn’s disease after treatment with antibodies against tumor necrosis factor. Clin Gastroenterol Hepatol. 2019;18:1545–52.CrossRef
11.
Zurück zum Zitat Biancheri P, Giuffrida P, Docena GH, et al. The role of transforming growth factor (TGF)-β in modulating the immune response and fibrogenesis in the gut. Cytokine Growth Factor Rev. 2014;25:45–55.CrossRef Biancheri P, Giuffrida P, Docena GH, et al. The role of transforming growth factor (TGF)-β in modulating the immune response and fibrogenesis in the gut. Cytokine Growth Factor Rev. 2014;25:45–55.CrossRef
12.
Zurück zum Zitat Wilson MS, Madala SK, Ramalingam TR, et al. Bleomycin and IL-1β-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med. 2010;207:535–52.CrossRef Wilson MS, Madala SK, Ramalingam TR, et al. Bleomycin and IL-1β-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med. 2010;207:535–52.CrossRef
13.
Zurück zum Zitat Biancheri P, Pender SLF, Ammoscato F, et al. The role of interleukin 17 in Crohn’s disease-associated intestinal fibrosis. Fibrogenes Tissue Repair. 2013;6:13.CrossRef Biancheri P, Pender SLF, Ammoscato F, et al. The role of interleukin 17 in Crohn’s disease-associated intestinal fibrosis. Fibrogenes Tissue Repair. 2013;6:13.CrossRef
14.
Zurück zum Zitat Lichtenstein GR, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn’s disease. Am J Gastroenterol. 2006;101:1030–8.CrossRef Lichtenstein GR, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn’s disease. Am J Gastroenterol. 2006;101:1030–8.CrossRef
15.
Zurück zum Zitat Bouhnik Y, Carbonnel F, Laharie D, et al. Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2017;67:53–60.CrossRef Bouhnik Y, Carbonnel F, Laharie D, et al. Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2017;67:53–60.CrossRef
16.
Zurück zum Zitat Louis E, Boverie J, Dewit O, et al. Treatment of small bowel subocclusive Crohn’s disease with infliximab: an open pilot study. Acta Gastroenterol Belg. 2007;70:15–9.PubMed Louis E, Boverie J, Dewit O, et al. Treatment of small bowel subocclusive Crohn’s disease with infliximab: an open pilot study. Acta Gastroenterol Belg. 2007;70:15–9.PubMed
17.
Zurück zum Zitat Zorzi F, Zuzzi S, Onali S, et al. Efficacy and safety of infliximab and adalimumab in Crohn’s disease: a single centre study. Aliment Pharmacol Ther. 2012;35:1397–407.CrossRef Zorzi F, Zuzzi S, Onali S, et al. Efficacy and safety of infliximab and adalimumab in Crohn’s disease: a single centre study. Aliment Pharmacol Ther. 2012;35:1397–407.CrossRef
18.
Zurück zum Zitat D’Amico F, Pugliese N, Peyrin-Biroulet L, Danese S. Efficacy of anti-TNFα drugs in patients with stricturing Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2020;14:347–53.CrossRef D’Amico F, Pugliese N, Peyrin-Biroulet L, Danese S. Efficacy of anti-TNFα drugs in patients with stricturing Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2020;14:347–53.CrossRef
19.
Zurück zum Zitat Murate K, Nakamura M, Fujishiro M. A case where administration of ustekinumab maintained the intestinal patency after balloon dilation for small intestinal stenosis caused by Crohn’s disease. Inflamm Bowel Dis. 2019;25:e140.CrossRef Murate K, Nakamura M, Fujishiro M. A case where administration of ustekinumab maintained the intestinal patency after balloon dilation for small intestinal stenosis caused by Crohn’s disease. Inflamm Bowel Dis. 2019;25:e140.CrossRef
Metadaten
Titel
Ustekinumab is effective against small bowel lesions in Crohn’s disease: two case reports
verfasst von
Kentaro Murate
Masanao Nakamura
Takeshi Yamamura
Keiko Maeda
Tsunaki Sawada
Yasuyuki Mizutani
Eri Ishikawa
Naomi Kakushima
Kazuhiro Furukawa
Eizaburo Ohno
Takashi Honda
Hiroki Kawashima
Masatoshi Ishigami
Mitsuhiro Fujishiro
Publikationsdatum
28.10.2020
Verlag
Springer Singapore
Erschienen in
Clinical Journal of Gastroenterology / Ausgabe 1/2021
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-020-01242-0

Weitere Artikel der Ausgabe 1/2021

Clinical Journal of Gastroenterology 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.